EA201692280A1 - Соединения для лечения спинальной мышечной атрофии - Google Patents
Соединения для лечения спинальной мышечной атрофииInfo
- Publication number
- EA201692280A1 EA201692280A1 EA201692280A EA201692280A EA201692280A1 EA 201692280 A1 EA201692280 A1 EA 201692280A1 EA 201692280 A EA201692280 A EA 201692280A EA 201692280 A EA201692280 A EA 201692280A EA 201692280 A1 EA201692280 A1 EA 201692280A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- connections
- treatment
- muscular atrophy
- spinal muscular
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В настоящем изобретении предложены соединения формулы (I)где A, R, Rи Rявляются такими, как указано в описании изобретения, а также их фармацевтически приемлемые соли. Также настоящее изобретение относится к получению соединений формулы (I), содержащих их фармацевтических композиций и их применению в качестве лекарственных средств.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 | |
| PCT/EP2015/060343 WO2015173181A1 (en) | 2014-05-15 | 2015-05-11 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201692280A1 true EA201692280A1 (ru) | 2018-07-31 |
| EA035068B1 EA035068B1 (ru) | 2020-04-23 |
Family
ID=53175048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201692280A EA035068B1 (ru) | 2014-05-15 | 2015-05-11 | Соединения для лечения спинальной мышечной атрофии |
| EA202090486A EA202090486A3 (ru) | 2014-05-15 | 2015-05-11 | Соединения для лечения спинальной мышечной атрофии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090486A EA202090486A3 (ru) | 2014-05-15 | 2015-05-11 | Соединения для лечения спинальной мышечной атрофии |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (ru) |
| EP (3) | EP3663296B1 (ru) |
| JP (1) | JP6236173B2 (ru) |
| KR (2) | KR102213740B1 (ru) |
| CN (1) | CN106459092B (ru) |
| AR (1) | AR100442A1 (ru) |
| AU (1) | AU2015261046C1 (ru) |
| BR (1) | BR112016026205B1 (ru) |
| CA (1) | CA2948561C (ru) |
| CL (1) | CL2016002836A1 (ru) |
| CR (1) | CR20160518A (ru) |
| DK (1) | DK3143025T3 (ru) |
| EA (2) | EA035068B1 (ru) |
| ES (2) | ES2761423T3 (ru) |
| FR (1) | FR21C1039I2 (ru) |
| HR (2) | HRP20230637T1 (ru) |
| HU (2) | HUE046491T2 (ru) |
| IL (2) | IL248653B (ru) |
| LT (1) | LTPA2021010I1 (ru) |
| MA (2) | MA51988A (ru) |
| MX (1) | MX371050B (ru) |
| MY (1) | MY174284A (ru) |
| NL (1) | NL301128I2 (ru) |
| NO (1) | NO2021035I1 (ru) |
| NZ (1) | NZ725008A (ru) |
| PE (1) | PE20170128A1 (ru) |
| PH (1) | PH12016502081A1 (ru) |
| PL (2) | PL3663296T3 (ru) |
| PT (1) | PT3143025T (ru) |
| RS (1) | RS59718B1 (ru) |
| SG (1) | SG11201609497TA (ru) |
| SI (2) | SI3143025T1 (ru) |
| TW (1) | TWI667239B (ru) |
| UA (1) | UA119670C2 (ru) |
| WO (1) | WO2015173181A1 (ru) |
| ZA (1) | ZA201607026B (ru) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116981C2 (uk) | 2012-02-10 | 2018-06-11 | ПіТіСі ТЕРАП'ЮТІКС, ІНК. | Сполуки для лікування спінальної м'язової атрофії |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| JP6659841B2 (ja) * | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| AU2016351919B2 (en) * | 2015-11-12 | 2020-11-12 | F. Hoffmann-La Roche Ag | Compounds for treating amyotrophic lateral sclerosis |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| MX2021001091A (es) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. |
| US11702646B2 (en) | 2016-11-28 | 2023-07-18 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| MX2019014514A (es) | 2017-06-05 | 2020-07-20 | Ptc Therapeutics Inc | Compuestos para tratar la enfermedad de huntington. |
| EP3638318A4 (en) | 2017-06-14 | 2021-03-17 | PTC Therapeutics, Inc. | METHOD OF MODULATION OF RNA SPLICING |
| EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3075968C (en) | 2017-09-22 | 2023-04-04 | F. Hoffmann-La Roche Ag | Process for the preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| JP7423515B2 (ja) * | 2017-10-03 | 2024-01-29 | エフ． ホフマン－ラ ロシュ アーゲー | Ｓｍａの新たな処置 |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| BR112020026637A2 (pt) | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| EP4434990A1 (en) | 2018-06-27 | 2024-09-25 | PTC Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| JP2022505098A (ja) | 2018-10-19 | 2022-01-14 | エフ．ホフマン－ラ ロシュ アーゲー | ピリド［１，２－ａ］ピリミジン－４－オン誘導体の新規な形態、その製剤およびその製造プロセス |
| CN113966219A (zh) | 2019-06-12 | 2022-01-21 | 豪夫迈·罗氏有限公司 | Sma的新治疗方法 |
| EP4004003A1 (en) | 2019-07-31 | 2022-06-01 | Teva Pharmaceuticals International GmbH | Solid state forms of risdiplam and process for preparation thereof |
| WO2022048675A1 (zh) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Risdiplam晶型及其制备方法和用途 |
| WO2022162107A1 (en) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Crystalline form of risdiplam |
| EP4308577A1 (en) * | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | New thiadiazolopyrimidone derivatives |
| CR20230437A (es) | 2021-03-17 | 2023-10-16 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona |
| AU2022237836B2 (en) | 2021-03-18 | 2024-07-04 | F. Hoffmann-La Roche Ag | Process for preparing risdiplam |
| CN118055767A (zh) | 2021-10-06 | 2024-05-17 | 豪夫迈·罗氏有限公司 | 新颖的组合施用 |
| WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024069646A1 (en) * | 2022-09-26 | 2024-04-04 | Natco Pharma Limited | Improved process for the preparation of risdiplam and its intermediates |
| US20240173325A1 (en) | 2022-10-14 | 2024-05-30 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
| WO2024154148A1 (en) * | 2023-01-21 | 2024-07-25 | Harman Finochem Limited | Process for preparation of risdiplam, novel intermediates, and process for preparation thereof |
| WO2024218207A1 (en) | 2023-04-20 | 2024-10-24 | F. Hoffmann-La Roche Ag | Thieno[3,2-b]pyridine derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1093130C (zh) * | 1996-08-06 | 2002-10-23 | 辉瑞大药厂 | 被取代的吡啶并6,6－二环衍生物 |
| EP2215074B1 (en) | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| KR20100012134A (ko) * | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| JP2011529722A (ja) * | 2008-08-14 | 2011-12-15 | カーディアック ペースメイカーズ， インコーポレイテッド | 音響通信リンクの性能評価および適合 |
| CN104244944B (zh) * | 2011-12-30 | 2018-06-08 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩症的化合物 |
| UA116981C2 (uk) * | 2012-02-10 | 2018-06-11 | ПіТіСі ТЕРАП'ЮТІКС, ІНК. | Сполуки для лікування спінальної м'язової атрофії |
| WO2014012050A2 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
-
2015
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active IP Right Grant
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/en active Active
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/en not_active Withdrawn
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/en active Application Filing
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/en active Active
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 CA CA2948561A patent/CA2948561C/en active Active
- 2015-05-11 BR BR112016026205-0A patent/BR112016026205B1/pt active IP Right Grant
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active IP Right Grant
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-19 PH PH12016502081A patent/PH12016502081A1/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
- 2019-11-29 HR HRP20192159TT patent/HRP20192159T1/hr unknown
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 LT LTPA2021010C patent/LTPA2021010I1/lt unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| EA201891091A1 (ru) | Соединения ингибитора jak киназы для лечения респираторного заболевания | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA201590358A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| EA201691293A1 (ru) | Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h | |
| EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| TW201613864A (en) | Novel compounds | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG TJ TM |
|
| ND4A | Extension of term of a eurasian patent | ||
| ND4A | Extension of term of a eurasian patent | ||
| ND4A | Extension of term of a eurasian patent |